Hengyu Biotechnology specializes in comprehensive biosafety testing services, focusing on various aspects of biopharmaceutical development and quality control. Their offerings include virus clearance and inactivation research, cell bank testing, raw material testing, and quality control for cell and gene therapy products. The company emphasizes adherence to international compliance standards such as QP, CNAS, GLP, and cGMP, ensuring that their services meet rigorous regulatory requirements. They provide a range of analytical validation services, including AAV viral vector characterization and process residual testing, which are critical for the safety and efficacy of biopharmaceutical products.

In addition to their testing services, Hengyu Biotechnology offers solutions for cell line development, validation, and storage, as well as virus bank analysis and storage services. With a significant track record, the company has successfully submitted over 60 commercial projects, including 35 cases in collaboration with U.S. partners, and has worked with approximately 300 biopharmaceutical companies on over 600 projects. Their facilities boast over 8,000 square meters of laboratory space and advanced instrumentation, enabling them to handle a high throughput of production and regulatory submissions, including more than 400 IND/BLA projects annually.

China

Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. It is a comprehensive provider founded by a group of top scientists, dedicated to providing innovative solutions in the biotech and biopharma space.

Hengyu Biotechnology

Company Details